(VIANEWS) – The Market ended the session with IBA (IBAB.BR) rising 12.24% to €12.12 on Wednesday, following the last session’s downward trend. BEL 20 fell 0.04% to €4,195.75, following the last session’s downward trend on what was a somewhat down trend trading session today.
IBA’s last close was €10.80, 25.82% below its 52-week high of €14.56.
About IBA
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.27.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 44.89. Meaning, the purchaser of the share is investing €44.89 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.86%.
More news about IBA (IBAB.BR).
